Effects Of Daily Taurine Intake For 6 Months On Biological Age and Body Metabolism Indicators As Well As Physical Fitness In 55-75-year-old Women And Men

NCT06613542 | Completed

• 1 other identifier: 2024-253-S-CB
• Study Type: interventional
• Target: 90
• Locations: 1 country
• Sites: 1

Brief Summary

The goal of this clinical trial is to investigate the effect of taking 4 grams of taurine by older adults on aging processes over a period of 6 months. It will also check for effects of taurine on participant's physical fitness, metabolic and cognitive functions. The main question it aims to answer is:

• Does a supplementation with 4 g of taurine daily over a period of 6 months slow down biological aging in humans? Researchers will compare supplementation with taurine to a placebo (a look-alike substance that contains no drug) to reliably determine whether taurine has an effect. Participants will:
• Take 4g of taurine or a placebo every day for 6 months
• Visit the study site 4 times for checkups and tests: for a screening visit, at the beginning of the intervention, after 8 and 24 weeks

Conditions

Taurine; Aging, Biological; Physical Activity; Metabolic Health; Anti-Aging; Longevity; Dietary Supplement; DNA Methylation; Sport

Keywords

taurine; biological aging; metabolic health; anti-aging; epigenetic clock; aging; physical activity; cognition; Cellular Senescence; hallmarks of aging; humans; Dietary Supplements; longevity; Taurine Deficiency; Taurine Level; aging metabolism; longevity physiology; drug effects; DNA-methylation; aging ptoeomics; DNA methylation; taurine microbiome; taurine gut micorbiota; taurine cognition; taurine sport; taurine DNA methylation; nutritional medicine; sport biology; taurine physical fitness; taurine physical acitvity; taurine sport biology; taurine muscle strength; taurine pwc 130; Taurine HOMA IR; taurine mental health; taurine human aging; taurine cardiometabolic risk; taurine cardiometabolic health; taurine blood pressure; taurine fasting glucose; taurine inflammation; taurine biological aging

Outcome Measures

Primary Outcomes (2)

• Change From Baseline in Biological Age At 6 Months (Proteome Analysis)

  The primary objective of the study is to answer the following research question: Does a 6-month supplementation with 4g of taurine daily slow down biological aging in humans? Biological age will be determined using a plasma proteome analysis and established machine learning models based on plasma and urine samples. This will also include an analysis of organ-specific aging.

  pre-intervention (at time point 0) and post-intervention (at 24 weeks)

• Change From Baseline in Biological Age At 6 Months (DNA Methylation)

  The primary objective of the study is to answer the following research question: Does a 6-month supplementation with 4g of taurine daily slow down biological aging in humans? Biological age will be estimated by assessing DNA methylation patterns (epigenetic clock) from plasma, urine, and oral mucosa samples.

  pre-intervention (at time point 0) and post-intervention (at 24 weeks)

Secondary Outcomes (12)

• Change From Baseline In Cognitive Functions at 6 Months

  pre-intervention (at time point 0) and post-intervention (after 24 weeks)

• Change From Baseline In Cardiometabolic Risk Profile at 6 Months

  pre-intervention (at time point 0) and post-intervention (at 24 weeks)

• Change From Baseline In Cardiometabolic Risk Profile at 6 Months

  pre-intervention (at time point 0) and post-intervention (at 24 weeks)

• Change From Baseline In Cardiometabolic Risk Profile at 6 Months

  pre-intervention (at time point 0) and post-intervention (at 24 weeks)

• Change From Baseline In Cardiometabolic Risk Profile at 6 Months

  pre-intervention (at time point 0) and post-intervention (at 24 weeks)

Study Arms (2)

4g of taurine daily

ACTIVE COMPARATOR

Intervention group (4g of taurine/day): 2g of taurine (4 capsules, 500mg each) in the morning and 2g of taurine (4 capsules, 500mg each) in the evening for 6 months

Dietary Supplement: 4g of taurine daily

Placebo

PLACEBO COMPARATOR

Dietary Supplement: Placebo

Interventions

4g of taurine daily DIETARY_SUPPLEMENT

Intervention group (4g of taurine/day): 2g of taurine (4 capsules, 500mg each) in the morning and 2g of taurine (4 capsules, 500mg each) in the evening for 6 months

4g of taurine daily

Placebo DIETARY_SUPPLEMENT

Controll group (4g of placebo/day): 2g of placebo (4 capsules, 500mg each) in the morning and 2g of placebo (4 capsules, 500mg each) in the evening for 6 months

Placebo

Eligibility Criteria

• Age: 55 Years - 75 Years
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• women or men
• Age 55 - 75
• BMI 22 - 30 kg/m²
• written consent

You may not qualify if:

• Acute or chronic inflammation (e.g. flu infection)
• Severe chronic illness (e.g., Type 1 or Type 2 diabetes mellitus, COPD, renal insufficiency)
• Myocardial infarction or stroke in the previous 6 months
• Psychiatric disorder, including depression or dementia
• Weight change of ≥ 5 kg in the last 6 months

Sponsors & Collaborators

• Technical University of Munich: lead
• Stanford University: collaborator
• Rutgers University: collaborator
• Universitaet Innsbruck: collaborator
• LMU Klinikum: collaborator

Study Sites (1)

Institute for Nutritional Medicine of Technical University of Munich

Munich, 80992, Germany

Location

Related Publications (2)

• Oh HS, Rutledge J, Nachun D, Palovics R, Abiose O, Moran-Losada P, Channappa D, Urey DY, Kim K, Sung YJ, Wang L, Timsina J, Western D, Liu M, Kohlfeld P, Budde J, Wilson EN, Guen Y, Maurer TM, Haney M, Yang AC, He Z, Greicius MD, Andreasson KI, Sathyan S, Weiss EF, Milman S, Barzilai N, Cruchaga C, Wagner AD, Mormino E, Lehallier B, Henderson VW, Longo FM, Montgomery SB, Wyss-Coray T. Organ aging signatures in the plasma proteome track health and disease. Nature. 2023 Dec;624(7990):164-172. doi: 10.1038/s41586-023-06802-1. Epub 2023 Dec 6.

  PMID: 38057571 BACKGROUND

• Singh P, Gollapalli K, Mangiola S, Schranner D, Yusuf MA, Chamoli M, Shi SL, Lopes Bastos B, Nair T, Riermeier A, Vayndorf EM, Wu JZ, Nilakhe A, Nguyen CQ, Muir M, Kiflezghi MG, Foulger A, Junker A, Devine J, Sharan K, Chinta SJ, Rajput S, Rane A, Baumert P, Schonfelder M, Iavarone F, di Lorenzo G, Kumari S, Gupta A, Sarkar R, Khyriem C, Chawla AS, Sharma A, Sarper N, Chattopadhyay N, Biswal BK, Settembre C, Nagarajan P, Targoff KL, Picard M, Gupta S, Velagapudi V, Papenfuss AT, Kaya A, Ferreira MG, Kennedy BK, Andersen JK, Lithgow GJ, Ali AM, Mukhopadhyay A, Palotie A, Kastenmuller G, Kaeberlein M, Wackerhage H, Pal B, Yadav VK. Taurine deficiency as a driver of aging. Science. 2023 Jun 9;380(6649):eabn9257. doi: 10.1126/science.abn9257. Epub 2023 Jun 9.

  PMID: 37289866 BACKGROUND

MeSH Terms

Conditions

Motor Activity

Condition Hierarchy (Ancestors)

Behavior

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: RANDOMIZED
• Masking: QUADRUPLE
• Who Masked: PARTICIPANT, CARE PROVIDER, INVESTIGATOR, OUTCOMES ASSESSOR
• Purpose: PREVENTION
• Intervention Model: PARALLEL
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Prof. Dr. med. Hans Hauner

Study Record Dates

• First Submitted: September 17, 2024
• First Posted: September 26, 2024
• Study Start: September 25, 2024
• Primary Completion: November 13, 2025
• Study Completion: November 13, 2025
• Last Updated: November 21, 2025

Record last verified: 2025-11

Data Sharing

• IPD Sharing: Will not share

Locations

DE (1)